Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects

Abstract Diabetes mellitus (DM) is a metabolic disorder that leads to the destruction of various tissues including bones. The pathogenesis of osteoporosis (OP) varies in DM due to many specific factors. DM increases the risk of fracture as well as post-fracture mortality. It is because of this fact...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of endocrinology and metabolism Vol. 29; no. 1; pp. 32 - 38
Main Authors Durgia, Harsh, Palui, Rajan, Sahoo, Jayaprakash, Kamalanathan, Sadishkumar, Naik, Dukhabandhu
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer - Medknow 2025
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer Medknow Publications
Edition2
Subjects
abaloparatide
anabolic
Complications and side effects
Diabetes
diabetes mellitus
Drug therapy
Fractures
Monoclonal antibodies
Osteoporosis
Pathogenesis
Prevention
Review
Review Article
Risk factors
romosozumab
teriparatide
India
romosozumab
Abaloparatide
diabetes mellitus
anabolic
teriparatide
osteoporosis
Online AccessGet full text

Cover

More Information
Summary:Abstract Diabetes mellitus (DM) is a metabolic disorder that leads to the destruction of various tissues including bones. The pathogenesis of osteoporosis (OP) varies in DM due to many specific factors. DM increases the risk of fracture as well as post-fracture mortality. It is because of this fact that OP treatment should not be neglected in patients with DM. OP therapy comprises anabolic as well as anti-resorptive agents. Primary OP as observed in post-menopausal women is associated with high bone turnover, whereas OP in DM is a disease of low bone turnover. Therefore, anabolic agents seem to be quite promising in cases of OP in DM. Although the anti-fracture efficacy of these drugs is proven beyond any doubt in the general population without DM, evidence in persons with DM is limited. Among the anabolic agents, teriparatide has the most evidence in favor of its efficacy and safety in persons with DM. Studies evaluating other anabolic agents such as abaloparatide and romosozumab in diabetic osteopathy are scarce in the literature. Future studies specifically in both type 1 and type 2 DM populations are needed to evaluate the effects of osteoanabolic agents.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2230-8210
2230-9500
DOI:10.4103/ijem.ijem_81_24